Raymond James Financial
AKBA icon

Raymond James Financial’s Akebia Therapeutics AKBA Stock Holding History

Raymond James Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66K Sell
57,902
-15,000
-21% -$17.9K ﹤0.01% 5225
2026
Q1 		$101K Sell
72,902
-7,675
-10% -$10.5K ﹤0.01% 5032
2025
Q4 		$130K Buy
80,577
+10,792
+15% +$22.6K ﹤0.01% 4879
2025
Q3 		$191K Buy
69,785
+10,283
+17% +$34.2K ﹤0.01% 4637
2025
Q2 		$217K Buy
59,502
+8,568
+17% +$23.5K ﹤0.01% 4479
2025
Q1 		$97.8K Buy
50,934
+6,186
+14% +$12.6K ﹤0.01% 4550
2024
Q4 		$85K Buy
+44,748
New +$77.7K ﹤0.01% 4548

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Raymond James Financial's AKBA Position: Q2 2026 in Review

Raymond James Financial reduced its Akebia Therapeutics (AKBA) stake by 21% in Q2 2026, selling an estimated $17.9K and leaving 57,902 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #5225.

Raymond James Financial first reported a position in AKBA in Q4 2024 and has held it in 7 quarters since. The position peaked at $217K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Raymond James Financial held 57,902 shares of Akebia Therapeutics worth $66K as of Q2 2026.
  • Raymond James Financial sold 15,000 Akebia Therapeutics shares in Q2 2026, an estimated $17.9K.
  • Akebia Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5225 holding.
  • Raymond James Financial first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Akebia Therapeutics position peaked at $217K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.